Swiss diagnostic solutions developer Abionic has reported positive results from an observational study of Pancreatic Stone Protein (PSP) test for the detection of sepsis.
Sepsis is a life-threatening condition characterised by organ dysfunction. The disease is a considerable threat to global health, with nearly 27-30 million people affected yearly.
It is responsible for one death every three seconds. Treatment within an hour can increase the survival rate by more than 80%.
Based on the company’s abioSCOPE platform, the point-of-care sepsis test provides results within five minutes using a capillary blood drop, allowing early detection and intervention.
The observational study investigated performance characteristics of the test in 300 adults who were at high risk of developing sepsis. It involved patients from 14 ICU sites across the UK and Italy, as well as Switzerland and France.
Abionic said that bedside PSP measurement on the abioSCOPE platform provides a correlation with the sepsis onset.
Study investigators observed that most of the participants who went on to develop sepsis had high PSP concentration values nearly 24 hours before the diagnosis with the existing standard of care.
The company intends to publish the results from the PSP test study next year.
Abionic chief scientific officer Fabien Rebeaud said: “Our study demonstrates that from a drop of blood and in five minutes sepsis can be identified several dozen of hours upfront than today’s standard of care.
“This opens tremendous perspectives for the improvement of the diagnosis of sepsis and its timely, optimal clinical management, for the benefit of the patient.”
Founded in 2010, Abionic developed nanotechnology-based abioSCOPE as a portable, universal diagnostic device. The company commercialises a test to measure respiratory allergens and total IgE, as well as another one to identify iron deficiencies.